Inflammatory Bowel Disease: Why Symptoms Going Quiet Isn't Enough, and What "Remission" Actually Means

Inflammatory bowel disease (IBD) — an umbrella that covers Crohn's disease and ulcerative colitis — is a chronic condition in which the immune system attacks healthy bowel tissue, producing real inflammation and ulceration that can be seen through a scope. That is exactly what separates it from irritable bowel syndrome. As Cleveland Clinic puts it in one blunt line: "IBD involves inflammation, but IBS doesn't." And the idea this whole article rests on is simpler than it sounds and harder to accept: symptoms going quiet does not prove the inflammation stopped — which is why modern guidelines no longer accept "I feel better" as a treatment target on its own.

This article is educational only and is not a substitute for your doctor's diagnosis or treatment plan. If you have persistent digestive symptoms — especially with bleeding or weight loss — the right place for this conversation is a gastroenterologist's clinic, not a search engine.

What is inflammatory bowel disease, and why isn't it "just IBS"? 🔬

Cleveland Clinic defines IBD as "diseases that cause chronic inflammation in your gastrointestinal (GI) tract," and describes the mechanism directly: "IBD happens when immune system cells in your GI tract mistakenly attack healthy tissue, causing inflammation." The problem, in other words, is not that the bowel is "sensitive" to food. It is a misdirected immune response that damages the wall itself.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes Crohn's disease as "a chronic disease that causes inflammation in the digestive tract," and notes that experts believe "genes, abnormal immune reactions, and the microbiome play a role." Notice what is not on that list: neither food alone nor stress alone.

The core difference: inflammation you can see vs. symptoms you can feel

Two people can describe almost the same complaint — abdominal pain, a change in bowel habit, bloating, fatigue — while one has irritable bowel syndrome and the other has inflammatory bowel disease. The difference does not show up in the description. It shows up as objective inflammation measurable in stool and blood, visible on endoscopy and confirmed on biopsy. Which is why the most dangerous sentence a patient can say to themselves is: "I know my body, this is just IBS."

Crohn's disease and ulcerative colitis: two diseases under one label

Mayo Clinic summarises the differences that actually change diagnosis, monitoring and treatment:

• Location: "Ulcerative colitis is only in the large intestine, called the colon," whereas "Crohn's disease can affect any part of the digestive tract, from the mouth to the anus."
• Continuity: ulcerative colitis "usually starts in the rectum and extends upward in a continuous line with no gaps," while Crohn's "often skips areas, meaning there are often healthy areas of tissue between inflamed spots."
• Depth: in ulcerative colitis "the inflammation is limited to the mucosal layer. This is the innermost lining of the colon," while in Crohn's "inflammation can involve deeper layers of the intestinal wall" — the depth that explains strictures, fistulas and abscesses.
• Typical symptoms: ulcerative colitis presents with "bloody diarrhea, a sudden, urgent need to use the bathroom," while Crohn's typically presents with "belly pain with often nonbloody diarrhea and unintended weight loss."

These are not two versions of one disease. As the section on smoking will show, some risk factors even point in opposite directions.

Which symptoms should never be postponed? 🚩

Cleveland Clinic lists among the common features: "Lower abdominal pain," "Blood in your poop (stool)," "Chronic diarrhea," "Fatigue," and "Unintended weight loss." It also names signs that warrant emergency care, including fever, "severe abdominal cramping or pain," "severe nausea and vomiting," "rectal bleeding with clots," and a "swollen abdomen."

Two signals get missed because they don't feel "digestive": symptoms that wake you from sleep, and weight loss you didn't try for. A functional disorder rarely wakes its owner at night; inflammation does. And if bleeding is what worries you, there are common and entirely benign causes of rectal bleeding — we covered them separately in hemorrhoids and anal fissures — but the rule there is the rule here: bleeding is not a diagnosis you give yourself.

How is it diagnosed, and why does the path often start with a cheap stool test? 🧪

A final IBD diagnosis is built from a package: clinical history, blood tests, stool tests, imaging, and endoscopy with biopsy. But the step that makes the practical difference early on is often one simple test — faecal calprotectin.

What calprotectin actually measures

Calprotectin is a protein released by white blood cells when they gather in the bowel wall, so a raised level in stool means inflammatory cells are present there. That is why it is useful for separating inflammatory from functional.

The UK's National Institute for Health and Care Excellence (NICE), in diagnostics guidance DG11, recommends faecal calprotectin testing "to support clinicians with the differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) in adults with recent onset lower gastrointestinal symptoms" — provided cancer is not suspected and laboratory quality assurance is in place. It makes a parallel recommendation for children with suspected IBD referred for specialist assessment.

The systematic review and economic evaluation prepared for that guidance reached a practical conclusion: "The same cut-off should be used in primary and secondary care: 50 µg/g." One included study recorded a high negative predictive value of 94%, and the reviewers noted that "over 60% of colonoscopies in this group of adult patients have found no abnormalities" — meaning the test can spare many people an invasive procedure they do not need.

But the test is not a diagnosis

Here is where the mistake runs in the opposite direction. A high calprotectin does not mean "Crohn's" — it can also rise with intestinal infection or non-steroidal anti-inflammatory drugs. Calprotectin is a triage tool that decides who needs a scope quickly; endoscopy with biopsy settles the name, extent and severity. The American College of Gastroenterology (ACG) 2025 Crohn's disease guideline references a "fecal calprotectin cut-off of >50-100 mg/g to distinguish inflammatory from non-inflammatory disease" — a triage threshold, not a verdict.

The spine: why "I feel better" is no longer a treatment target 🎯

For decades the goal of IBD treatment was to silence symptoms. Then an awkward observation accumulated: patients who felt completely well whose scopes showed active ulceration — and the reverse.

A 2024 review in the World Journal of Gastroenterology on treat-to-target in Crohn's disease states it plainly: "clinical symptoms correlate poorly with mucosal inflammation," adding that patient-reported outcome measures "are best used in conjunction with objective measures of inflammation."

STRIDE-II: three layers, not one

On that basis, the STRIDE-II initiative of the International Organization for the Study of IBD (published in Gastroenterology in 2021) set targets ordered in time rather than a single finish line. As that review presents them:

• Immediate target (under 3 months): clinical response — a decrease of 50% or more in patient-reported outcome scores.
• Intermediate target (3–6 months): clinical remission, together with normalisation of biomarkers — CRP below the upper limit of normal, and faecal calprotectin in a range usually quoted between 100 and 250 µg/g.
• Long-term target (6–12 months): endoscopic healing — absence of ulcers by defined scoring — plus absence of disability and restored quality of life.

The same review notes that transmural healing and histologic healing were not endorsed as formal treatment targets by STRIDE-II, and are described as adjunctive and in need of further study. That caveat matters: even ambitious targets come with published limits.

What current guidelines say

• The American Gastroenterological Association (AGA), in its guideline on biomarkers in ulcerative colitis: "AGA suggests a monitoring strategy that combines biomarkers and symptoms, rather than symptoms alone," using a faecal calprotectin threshold of 150 µg/g to separate normal from elevated. It also states honestly that it "makes no recommendation in favor of, or against, a biomarker-based monitoring strategy over an endoscopy-based monitoring strategy."
• The updated 2025 ACG guideline for ulcerative colitis in adults (Rubin, Ananthakrishnan, Siegel, Barnes and Long, American Journal of Gastroenterology): "The primary aim of treatment is to achieve and maintain long-term remission without the use of steroids," with a recommendation to treat "to achieve endoscopic improvement (defined as resolution of inflammatory changes [MES 0 or 1])" in order to increase sustained remission and prevent hospitalisation and surgery — and to use faecal calprotectin "to assess response to therapy, to evaluate suspected relapse, and during maintenance."
• The updated 2025 ACG guideline for Crohn's disease (Lichtenstein, Loftus, Isaacs et al., American Journal of Gastroenterology 2025;120(6):1225–1264): "mucosal healing on endoscopy remains the goal of therapy." The same update suggests "against requiring patients to fail conventional therapies such as thiopurines or methotrexate before starting advanced therapies," because "new evidence emerged showing early intervention with advanced therapy is superior to accelerated step-up therapy."

The practical takeaway for a patient reading this: ask your doctor not only "am I better?" but "what number are we chasing, and when do we re-measure it?" That is the essence of what the guidelines call treat-to-target.

The window of opportunity: why delay costs more than it looks ⏳

In a recent regional study published in Intestinal Research in 2026 from the United Arab Emirates (Swaid and colleagues; 243 patients — 148 Crohn's disease, 95 ulcerative colitis), the median time from symptom onset to diagnosis was 4.0 months for Crohn's (IQR 1.5–9.0) and 3.0 months for ulcerative colitis (IQR 1.0–7.0). The authors frame the urgency clearly: "early intervention, specifically within the first 18 months of disease onset, can halt the progression from inflammation to irreversible bowel damage." They cite prior research linking diagnostic delay in Crohn's to "an 88% increase in the odds of stricturing disease and a 124% increase in intestinal surgery."

And because honesty beats drama, the study carries its own brake: in this particular cohort, "diagnostic delay did not predict AT exposure or surgical risk," and the researchers suggest that rapid therapeutic escalation (a median of 4.5 months to first biologic in Crohn's) may offset the effect of delay where the health system allows effective treatment to start quickly. The message is not that delay is inevitably catastrophic — it is that speed of access to effective treatment is what buys the time back.

And in our region?

In a systematic review and meta-analysis published in Inflammatory Intestinal Diseases in 2021 (Mosli and colleagues; 16 studies, eight of them from Saudi Arabia), the pooled incidence in the Arab world was 2.33 per 100,000 persons per year (95% CI 1.2–3.4) for ulcerative colitis and 1.46 (95% CI 1.03–1.89) for Crohn's disease. The more telling figure is the trend: one Saudi study documented that Crohn's incidence rose "from 0.32 per 100,000 persons per year between 1983 and 1993 to 1.66 per 100,000 persons per year between 1994 and 2004," and the authors conclude that "there is a growing incidence of IBD in the Arab world."

For a Saudi reader that means one thing: the disease is no longer "rare here," and it should not be dismissed simply because a patient is young or the symptoms "look ordinary."

The disease does not stop at the bowel 🦴

IBD surprises many patients by being systemic. According to the Crohn's & Colitis Foundation: "Between 25-40% of IBD patients experience EIMs, commonly in the joints, skin, bones, eyes, kidneys, and liver." Specifically:

• Joints: arthritis is "the most common extraintestinal complication," affecting "as many as 30% of patients with Crohn's or colitis."
• Skin: "Up to 20% of people with IBD experience skin extraintestinal complications."
• Bones: "As many as 30% to 60% of IBD patients have lower-than-average bone density" — which connects directly to what we covered in vitamin D and bone health.
• Eyes: "Approximately 10% of IBD patients experience eye problems." Liver: serious liver disease in "about 5% of people with IBD."
• Anemia: "Approximately one in three patients with IBD has anemia" — a good reason to read our piece on iron deficiency and why a hemoglobin test isn't enough.

The point of these numbers is not fear but connection: recurrent joint pain or recurrent eye inflammation in someone with IBD is not a coincidence to be treated in a separate clinic — it is information that belongs to the doctor managing the disease.

Food: it didn't cause the disease, it doesn't cure it alone — but it isn't irrelevant 🍽️

This is the first question nearly every patient asks, and it deserves an honest answer in stages.

First: does food cause IBD?

Cleveland Clinic answers the question "Does diet cause IBD?" with two words and a caveat: "No, but you may notice that your symptoms get worse after you consume certain foods or liquids." That distinction frees patients from pointless guilt while keeping their own observation as useful information rather than a universal law.

It is also worth separating IBD from wheat and gluten disorders. They differ in mechanism and in diagnosis, and avoiding gluten is not a treatment for Crohn's disease or ulcerative colitis — it should never be presented as one.

Second: what do guidelines say about diets?

The updated ACG Crohn's guideline (2025) allows consideration of "Mediterranean or specific carbohydrate diets in select low-risk patients with mild disease, provided close monitoring is ensured." Count the conditions in a single sentence: select, low-risk, mild disease, close monitoring. Diet here is a clinical option with strings attached, not a replacement for treatment.

Third: the trial everyone cites — the Crohn's Disease Exclusion Diet

In a randomised controlled trial published by Levine and colleagues in Gastroenterology in 2019, 78 children with mild-to-moderate Crohn's disease were randomised to the Crohn's Disease Exclusion Diet plus partial enteral nutrition (CDED + PEN) or to exclusive enteral nutrition (EEN). The results:

• Tolerability: "The combination of CDED and PEN was tolerated in 39 children (97.5%), whereas EEN was tolerated by 28 children (73.6%)."
• Week 12 remission: "28 (75.6%) of 37 children given CDED plus PEN were in corticosteroid-free remission compared with 14 (45.1%) of 31 children given EEN" — a statistically significant difference.

That is a strong result and deserves to be quoted — with its conditions attached. The trial was in children with mild-to-moderate disease, under close medical and dietetic supervision, and the diet is a staged written protocol, not a list of banned foods assembled from the internet. Exclusive enteral nutrition, likewise, is a medical therapy rather than a personal choice.

Fourth: during a flare vs. during remission

The practical rule is simple: what suits a flare may not suit remission. Many patients are advised to reduce coarse fibre and residue temporarily during severe flares or with a stricture, while the goal in remission is a varied, nourishing diet that doesn't restrict for no reason. Which is why the worst advice you can give someone with IBD is a fixed lifetime list of forbidden foods — the right approach is a plan that changes with the state of the disease, written by their doctor or dietitian.

Smoking: the lever that runs in opposite directions 🚭

Here it becomes obvious that Crohn's and ulcerative colitis are not one disease. According to Crohn's & Colitis UK:

• "Smoking increases your risk of developing Crohn's," and "smoking makes Crohn's worse," with more flare-ups.
• "Smokers with Crohn's are twice as likely to experience recurrence after surgery."
• "If you stop smoking, your risk factors return to that of someone who has never smoked."
• In ulcerative colitis the picture differs: "You are less likely to develop Ulcerative Colitis if you smoke," and "it's not clear how smoking affects Ulcerative Colitis in people who already have it."

To be unmistakably clear: this is an epidemiological observation about one disease, not a recommendation to smoke — smoking remains one of the largest preventable causes of illness and death. The useful point is that quitting is a genuine therapeutic intervention in Crohn's disease, and anyone planning to quit while living with ulcerative colitis is best doing it in coordination with their medical team.

When should you see a doctor? 👨‍⚕️

See a doctor — rather than reaching for a painkiller or a diet — for any of the following:

1. Diarrhea lasting more than two weeks, or a clear and persistent change in bowel habit.
2. Blood in the stool, or repeated bleeding however minor it seems.
3. Unintended weight loss, or growth delay in a child or teenager.
4. Symptoms that wake you from sleep, or recurrent night-time abdominal pain.
5. Severe unexplained fatigue, pallor, or symptoms of anemia.
6. Recurrent fever alongside digestive symptoms, or joint pain or eye inflammation with them.
7. Pain, swelling or discharge around the anus (which can be an early sign of Crohn's).

Remember that chronic constipation or bloating alone are not usually signs of IBD; we covered those in chronic constipation. The purpose of this list is not to help you diagnose yourself — it is to help you recognise when waiting is the wrong decision.

An important note: do not stop your treatment or change its dose on your own because you "feel fine." That is precisely the situation this article argues about — feeling well may not reflect what is happening in the mucosa. Any adjustment goes through your treating physician.

Where does Bakery 8 fit into this? 🥖

Let's start with what we cannot claim: no bread treats Crohn's disease or ulcerative colitis, and no product in our store replaces your doctor or your treatment plan. More than that — and this is against our commercial interest but it is the truth: during an active flare or with an intestinal stricture, a patient may be advised to reduce fibre and residue temporarily, and at that stage our fibre-rich products may not be right for them. That decision belongs to a doctor or dietitian, not to a store.

What we can honestly say is narrower: many people in remission need a varied diet low in added sugars, and having options made with almond flour and no added sugar is simply a practical choice inside a plan their medical team writes — from bread to granola, crackers and sugar-free desserts. Our aim at Bakery 8 (مخبز ثمانية) in Riyadh, Saudi Arabia is to make sticking to a dietary plan easier — never to replace it. Healthy and delicious, with no medical promises.

Frequently asked questions ❓

Is inflammatory bowel disease the same as IBS?

No, and the difference is not one of severity. Cleveland Clinic states it plainly: "IBD involves inflammation, but IBS doesn't." In IBD the immune system attacks bowel tissue and produces ulceration visible on endoscopy and measurable in stool and blood tests, whereas IBS does not cause that structural damage even though its symptoms can be very distressing.

What does a high faecal calprotectin mean?

It means inflammatory cells are present in the bowel and you likely need deeper evaluation — not that you have Crohn's disease. Levels can also rise with intestinal infection or non-steroidal anti-inflammatory drugs. NICE recommends the test to support the IBD-versus-IBS differential; endoscopy with biopsy is what settles the final diagnosis.

If my symptoms disappear completely, is the disease under control?

Not necessarily, and that is this article's central point. The treat-to-target review notes that "clinical symptoms correlate poorly with mucosal inflammation," which is why STRIDE-II set staged targets that include normalising biomarkers and then endoscopic healing — not symptoms alone. Ask your doctor which objective target you are chasing and when it will be reassessed.

Is there a diet that treats inflammatory bowel disease?

There is no diet that stands alone as a treatment for patients in general. The strongest published dietary evidence is the trial by Levine and colleagues (Gastroenterology, 2019) in children with mild-to-moderate disease, where corticosteroid-free remission at week 12 reached 75.6% with the Crohn's Disease Exclusion Diet plus partial enteral nutrition. These are supervised therapeutic protocols, not diets a patient starts alone.

Is IBD hereditary? Is it contagious?

It is not contagious at all. Genetics is one factor among several; NIDDK notes that "genes, abnormal immune reactions, and the microbiome" play a role. Having an affected relative raises the probability and justifies earlier attention to symptoms, but it does not make the disease inevitable.

Why does my doctor ask about my joints, eyes and bones?

Because the disease is systemic. The Crohn's & Colitis Foundation reports that "between 25-40%" of patients experience extraintestinal manifestations, that arthritis affects "as many as 30%," and that "30% to 60%" have lower-than-average bone density. Telling your doctor about these symptoms is part of managing the disease itself, not a side complaint.

Conclusion 🌿

Inflammatory bowel disease is not "severe IBS," not the result of one wrong meal, and not a condition managed with a list of banned foods. It is a chronic immune-mediated disease that leaves a mark you can measure and see — which is exactly why its treatment targets moved from silencing symptoms to normalising biomarkers and then healing the mucosa. The two things worth taking away: don't postpone symptoms that carry warning signs, and ask your doctor what number the two of you are chasing.

And once your plan is settled with your medical team, Bakery 8 offers everyday options with no added sugar and no exaggerated promises. Healthy and delicious.

References 📚

• Cleveland Clinic — Inflammatory Bowel Disease (IBD): definition, causes, symptoms and diagnosis.
• Mayo Clinic — Ulcerative colitis vs. Crohn's disease.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH — Crohn's Disease.
• National Institute for Health and Care Excellence (NICE) — Diagnostics guidance DG11: Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel.
• NIHR Health Technology Assessment — Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation (NCBI Bookshelf).
• American Gastroenterological Association (AGA) — Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis.
• Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD — ACG Clinical Guideline Update: Ulcerative Colitis in Adults. American Journal of Gastroenterology, 2025.
• Lichtenstein GR, Loftus EV Jr, Isaacs KL, et al. — Updated ACG Clinical Guideline for the Management of Crohn's Disease. American Journal of Gastroenterology, 2025;120(6):1225–1264.
• Treat to target in Crohn's disease: a practical guide for clinicians. World Journal of Gastroenterology, 2024;30(1):50 — reporting the STRIDE-II targets (Turner D, et al., Gastroenterology, 2021).
• Levine A, Wine E, Assa A, et al. — Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology, 2019.
• Swaid TK, Hamzeh LR, Bukasa LL, Jess T, Quraishi MN — Rapid diagnosis and therapeutic mitigation in inflammatory bowel disease: utilizing the window of opportunity — findings from the UAE Epi-IBD study. Intestinal Research, 2026.
• Mosli M, Alawadhi S, Hasan F, Abou Rached A, Sanai F, Danese S — Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis. Inflammatory Intestinal Diseases, 2021.
• Crohn's & Colitis Foundation — Extraintestinal Complications of IBD.
• Crohn's & Colitis UK — Smoking or vaping and Crohn's Disease, Ulcerative Colitis or Microscopic Colitis.

Related keywords: inflammatory bowel disease, Crohn's disease, ulcerative colitis, faecal calprotectin, mucosal healing and remission, IBD vs IBS, treat-to-target, IBD symptoms, Crohn's Disease Exclusion Diet, extraintestinal manifestations.